My real worry about lower back is going to be getting insurance buy-in. This is going to be a hard problem to solve and will involve more PR than science.
Which is one reason IMO we need a big pharma global partnership deal for CLBP ... their experience and leverage would (obviously) be far greater than ours
GLTAH
Potential Market Size for Mesoblast products in US, page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.065(4.44%) |
Mkt cap ! $1.589B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.37 | $7.869M | 5.614M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 18967 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 11632 | 5 |
View Market Depth
| Last trade - 14.55pm 09/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |